Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
Int J Colorectal Dis. 2011 Jan;26(1):45-51. doi: 10.1007/s00384-010-1054-y. Epub 2010 Sep 1.
Although hyperfibrinogenemia has been reported in patients with colorectal cancer, neither its clinical implications nor the effect of chemoradiotherapy (CRT) on the fibrinogen levels have been fully investigated. We investigated the clinical significance of pre- and post-CRT fibrinogen levels in patients with rectal cancer.
The medical records of 82 patients with rectal cancer, who had received CRT followed by surgical resection, were retrospectively reviewed. The correlation between the clinicopathological variables and the pre- and post-CRT plasma fibrinogen levels, and that between the changes of fibrinogen, C-reactive protein (CRP), or carcinoembryonic antigen (CEA) levels after CRT and the pathological tumor regression grading was analyzed. Furthermore, the impact of post-CRT fibrinogen levels on the prognosis of these patients was assessed.
Plasma fibrinogen markedly decreased after CRT. The post-CRT fibrinogen level significantly correlated with lymphatic invasion, venous invasion, tumor size, depth of invasion, and the pathological tumor regression grading. The CRT-induced pathological tumor regression grading well correlated with the decrease of fibrinogen level, but not with that of CRP or CEA. Furthermore, patients with high post-CRT fibrinogen had significantly shorter disease-free survival.
Reduction of plasma fibrinogen induced by CRT should be a promising biomarker for evaluating the efficacy of CRT in rectal cancer patients.
虽然已有研究报道结直肠癌患者存在高纤维蛋白原血症,但纤维蛋白原的临床意义以及放化疗(CRT)对其水平的影响尚未得到充分研究。本研究旨在探讨直肠癌患者 CRT 前后纤维蛋白原水平的临床意义。
回顾性分析了 82 例接受 CRT 后行手术切除的直肠癌患者的病历资料。分析了纤维蛋白原的变化与临床病理变量、纤维蛋白原、C 反应蛋白(CRP)或癌胚抗原(CEA)水平在 CRT 后的变化与肿瘤病理消退分级之间的相关性。此外,还评估了 CRT 后纤维蛋白原水平对这些患者预后的影响。
CRT 后血浆纤维蛋白原显著降低。CRT 后纤维蛋白原水平与淋巴血管侵犯、静脉侵犯、肿瘤大小、浸润深度和肿瘤病理消退分级显著相关。CRT 诱导的肿瘤病理消退分级与纤维蛋白原水平的降低密切相关,而与 CRP 或 CEA 水平的降低无关。此外,CRT 后纤维蛋白原水平较高的患者无病生存率显著缩短。
CRT 诱导的血浆纤维蛋白原降低可能是评估直肠癌患者 CRT 疗效的有前途的生物标志物。